News stories about Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trillium Therapeutics earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.4948786618938 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
TRIL has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. HC Wainwright initiated coverage on shares of Trillium Therapeutics in a research report on Monday. They issued a “buy” rating and a $7.00 target price on the stock. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $18.00 target price on shares of Trillium Therapeutics in a research report on Friday, June 9th. Finally, Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Trillium Therapeutics currently has a consensus rating of “Buy” and an average price target of $14.95.
Shares of Trillium Therapeutics (TRIL) traded up 4.30% during trading on Thursday, reaching $4.85. 9,829 shares of the company were exchanged. The company’s market capitalization is $38.05 million. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $17.70. The stock’s 50 day moving average is $4.65 and its 200 day moving average is $5.60.